Antifibrotic effects of macropinocytosis inhibition in idiopathic pulmonary fibrosis

The Department of the Army Medical Command awarded Baylor College of Medicine a $320,000 project grant under the Military Medical Research and Development program (CFDA 12.420) for the period of March 1, 2022 through February 29, 2024. The grant will support research into the anti-fibrotic effects of macropinocytosis inhibition in idiopathic pulmonary fibrosis. Through the Military Medical Research and Development program, the Department of the Army aims to transform military and public health care by supporting innovative biomedical research with the goals of investigating medical solutions for battlefield care and transforming treatment for service members and the general public. This award will further those goals by exploring potential therapeutic approaches for idiopathic pulmonary fibrosis. All work will be conducted at Baylor College of Medicine's location in Houston, Texas.